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Abstract
Background: The majority of patients with community acquired-pneumonia (CAP) are treated in primary care and
the mortality in this group is very low. However, a small but significant proportion of patients who begin treatment
in the community subsequently require admission due to symptomatic deterioration. This study compared patients
who received community antibiotics prior to admission to those who had not, and looked for associations with
clinical outcomes.
Methods: This study analysed the Advancing Quality (AQ) Pneumonia database of patients admitted with CAP to
9 acute hospitals in the northwest of England over a 12-month period.
Results: There were 6348 subjects (mean age 72 [SD 16] years; gender ratio 1:1) admitted with CAP, of whom 17%
had been pre-treated with antibiotics. The in-hospital mortality was 18.6% for the pre-treatment group
compared to 13.2% in the “antibiotic naïve” group (p < 0.001). On multivariate analysis, age, male gender
and antibiotic pre-treatment were predictors of in-hospital mortality along with a history of cerebrovascular
accident, congestive cardiac failure, dementia, renal disease and cancer. After adjustment for CURB-65 score,
age, co-morbidities and pre-treatment with antibiotics remained as independent risk factors for in-hospital
mortality (OR 1.43, 95% CI 1.19–1.71).
Conclusion: CAP patients admitted to hospital were more likely to die during admission if they had received
antibiotics for the same illness pre-admission. Future studies should endeavor to determine the mechanisms
underlying this association, such as microbiological factors and the role of comorbidities. Patients hospitalized
with CAP despite prior antibiotic treatment in the community require close monitoring.
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Background
Community-acquired pneumonia (CAP) constitutes a
considerable worldwide burden in terms of morbidity,
mortality and emergency medical admissions [1]. At
the time of presentation to hospital up to 20% of pa-
tients diagnosed with CAP have been pre-treated with
antibiotics in primary care for symptoms of a lower
respiratory tract infection (LRTI) [2, 3]. A paucity of
high quality data exists as to whether prior antibiotic
therapy in the community is associated with an adverse
outcome following hospitalization. However, prior anti-
biotic therapy is usually a specific criterion excluding entry
into antibiotic clinical trials in CAP. CAP is observed with
increasing prevalence in the elderly, the immunosup-
pressed and in those with significant co-morbidity, which
are risk factors in themselves for mortality in pneumonia
[2, 4]. In any study examining this issue, adequate
separation of such variables from prior antibiotic therapy
is essential to truly define the contribution of the latter as
a potential risk factor in CAP. Advancing Quality (AQ) is
a National Health Service (NHS)-recognized initiative set
in the northwest of England, which aims to improve stan-
dards of healthcare delivery in alignment with national
guidelines and encompasses a variety of conditions,
including CAP [5]. This UK-based study involves analysis
of the AQ Pneumonia database to determine whether in-
hospital mortality in adults hospitalized with CAP is
associated with prior antibiotic treatment.
Methods
The AQ Pneumonia program requires participating
hospitals to submit data for all cases admitted with a
diagnosis of CAP on a rolling monthly basis. The
processes underpinning case identification and data
entry for the AQ Pneumonia program are outlined in
the supplement. For submission to the AQ program,
it is necessary for the diagnosis of CAP to be made
by a consultant physician following formal medical
review within 24 h of hospital admission, along with
compatible chest radiograph findings. For each case,
key measures integral to the optimal management of
CAP are captured; e.g. whether assessment of oxygenation
status and CAP severity index were documented, the time
to chest radiograph being performed and time to “1st dose
inpatient antibiotic administration”, and whether anti-
biotic selection was appropriate according to local guide-
lines. The AQ Pneumonia database specifically excludes
subjects who do not have an abnormal chest radio-
graph reported on admission, those referred to pallia-
tive care following senior medical review or those on
a “palliative care code” on hospital admission, those
entered into a clinical trial, those diagnosed with
hospital-acquired pneumonia (HAP), and subjects
where there is no documentation of a diagnosis of
pneumonia following senior consultant medical review
after admission.
For each case being submitted to the AQ Pneumonia
program, the official admission chest X-ray report (made
by a consultant radiologist) is examined by an independ-
ent administrator at the time of data entry into the AQ
program to ensure that it is compatible with a diagnosis
of CAP prior to acceptance. Each hospital participating
in the AQ Pneumonia program complies with regular
independent NHS audits in order to ensure accuracy of
data entry. For each case of CAP submitted to the AQ
Pneumonia database, it is also mandatory to record
(from analysis of the medical and prescribing records)
whether antibiotics were administered in primary care in
the 24 h prior to the admission episode, so called “prior-
treatment”.
For the analysis, in-patient mortality was defined as and
restricted to patients who were recorded as having died at
the end of their hospital stay. Patients who were
discharged alive and died later are not included in the
calculation. In-patient mortality was defined as patients
who have a coded discharge method as defined by the
NHS Data Dictionary (http://www.datadictionary.nhs.uk).
A 30-day readmission was defined as any emergency or
unplanned admission to hospital for the same patient
within 30 days of the discharge date of the original index
admission, while a 30-day readmission due to pneumonia
was defined as any readmission based on whether the pri-
mary diagnosis code of the readmission is pneumonia,
using the same ICD10 list used to identify the initial co-
hort. Patient comorbidities were identified using the
Charlson Comorbidity Index (CCI) as defined in the
Standardized Hospital Mortality Guide [6]. This uses
ICD10 diagnosis codes in the patient spell to identify if
the patient has any of the 17 different comorbidities listed,
in which each comorbidity is allocated a different weight
according to the burden of disease. The total comorbidity
score is the sum weight of the patient’s comorbidities. For
this study, analysis of all the CAP cases submitted by the 9
participating hospitals in the AQ Pneumonia program for
a 12-month period (April 2016–2017) was undertaken.
The 9 hospitals studied were required to submit all cases
of CAP to the AQ Pneumonia program during the study
period. The analysis was performed by a group comprising
respiratory physicians, a senior business intelligence ana-
lyst, a medical statistician, two healthcare managers and a
respiratory specialist nurse.
Statistical analysis
Demographic information was summarized using mean
and standard deviations for continuous data, unless the
data was not normally distributed. In this case, the
median and interquartile range was used to describe the
average and variability in the data. Categorical data was
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presented using counts and percentages. The data was
stratified depending on whether the patients had been
on antibiotic treatment prior to admittance. Following
this, formal hypothesis tests (using Pearson’s chi-squared
test) were undertaken to investigate possible differences
between comorbidities and home antibiotic prescribing,
and then between comorbidities and death. Logistic re-
gression was used to construct a multivariate model,
which combined demographic variables and comorbidi-
ties, along with antibiotic prescribing, to determine the
major predictors of death. A further series of logistic
regression models were constructed to determine the
risk of death for individual comorbidities and antibiotic
prescribing. Participant age and, where available, severity
of condition (CURB-65) were also included as significant
covariates in these models. To complete the analysis, anti-
biotic home prescribing and the risk of re-admittance with
pneumonia was investigated using the chi-squared test. In
all analysis, results were considered significant if p < 0.05.
All analysis was undertaken using SPSS version 22.
Results
A total of 6348 adults admitted with CAP were submit-
ted to the AQ Pneumonia database during the study
period. The study population demographics are outlined
in Table 1. The in-hospital mortality for the entire co-
hort was 14.4% (916/6348). There were 1059 subjects
(17%) “pre-treated” with antibiotics prior to admission
and 4973 (78%) who were not “pre-treated”. It was not
possible to determine whether antibiotics had been
administered pre-admission in 316 (5%) subjects.
The incidence of specific comorbidities in the study
population, along with the ICD-10 codes ascribed to
each condition, is listed in the Additional file 1:
Table S1. There were no subjects with a coded diagnosis
of human immunodeficiency virus (HIV) or acquired im-
mune deficiency syndrome (AIDS) in the cohort. Table 2
outlines the variables associated with in-hospital mortality
in the entire CAP cohort. In-hospital mortality was associ-
ated with advanced age, higher CCI, “pre-treatment” with
antibiotics in primary care and a higher CURB-65 score.
The in-hospital mortality was 18.6% (197/1059) in the
antibiotic “pre-treated” subjects, compared to 13.2% (658/
4973) in those not “pre-treated” (chi square 26.80, df = 2;
p < 0.001). In terms of specific co-morbidity, a history of
congestive cardiac failure (CCF), cerebrovascular accident
(CVA), myocardial infarction (MI), renal disease, demen-
tia, cancer (including metastatic) and paraplegia were all
associated with in-hospital mortality.
When comparing the antibiotic “pre-treated” cohort to
those not “pre-treated” with antibiotics, an elevated CCI
score was observed in the “pre-treated cohort” with a
non-significant trend observed for female gender. In
terms of specific co-morbidity, the incidence of congest-
ive cardiac failure (CCF) and renal disease was signifi-
cantly higher in the “pre-treated” cohort. No differences
were observed in terms of severity of pneumonia (distri-
bution of CURB-65 scores), age, gender or 30 day re-
admission rate (see Table 3).
After applying multivariate analysis (Table 4), the
following variables emerged as significant predictors of
in-hospital mortality: age, male gender, antibiotic pre-
treatment, along with the following co-morbidities:
CVA, CCF, dementia, renal disease and cancer. When
controlling for age, pre-treatment with antibiotics and
severity, gender was not a significant variable in these
models. The comorbidities MI (adjusted odds ratio
[aOR]1.40 [95% CI 1.09–1.79]), CVA (aOR 1.66 [95% CI
1.21–2.17]), CCF (aOR 2.06 [95% CI 1.69–2.51]),
dementia (aOR 1.36 [95% CI 1.09–1.70]), renal (aOR
1.35 [95% CI 1.09–1.66]), metastatic cancer (aOR 2.55
[95% CI 1.66–4.07]) and cancer (aOR 1.57 [95% CI
1.21–2.05]) were all significant predictors of death. In
each of these models antibiotic prescribing was also a sig-
nificant predictor of death (aOR 1.43 [95% CI 1.19–1.71]).
When the analysis was restricted to only those patients
with a CURB-65 score (3993 subjects), the CURB-65
score became a significant predictor of mortality
(Table 5). Although it should be noted that as the
CURB-65 variable only contained 6 categories, the vari-
able was included in the model as 5 dummy indicator
variables with the CURB-65 “Zero” score (547 observa-
tions) taken as reference. For this variable, the aOR
ranged from 1.5 to 16.9, although the 95% confidence
interval for the CURB-65 score of 5 was wide (6.2–45.8)
due to there being only 35 observations in this category.
Of the demographic variables age (aOR 1.03 [95% CI
1.02–1.04]), CCI (aOR 1.02 [95% CI 1.00–1.03]) and
pre-treatment with antibiotics (aOR 1.54 [95% CI 1.20–
1.99]) were significant predictors of mortality along with
three co-morbidity indicators: CCF (aOR 1.62, [95% CI
Table 1 Demographics of the study population
Age (mean/SD) 72 (16) years
Gender 3201 (50.4%) female
3147 (49.6%) male
Length of stay (median/IQR) 5 (3–11) days
Charlson Comorbidity Index (median/IQR) 6 (3–17)
Admission “CURB 65” score N (%)
CURB 65 score 0 547 (9%)
CURB 65 score 1 906 (14%)
CURB 65 score 2 1269 (20%)
CURB 65 score 3 992 (16%)
CURB 65 score 4 244 (3.8%)
CURB 65 score 5 35 (0.6%)
CURB 65 score not documented 2355 (37%)
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1.22–2.17]), cancer (aOR 1.40 [95% CI 1.01–1.95]) and
metastatic cancer (aOR 1.88 [95% CI 1.03–3.47]).
Of the 5432 subjects who survived the index admis-
sion, 1095 (21%) were readmitted within 30 days. Of
these, 362 (33.1%) were specifically coded for pneu-
monia as a primary diagnosis. The administration of
pre-hospital antibiotics was not associated with a sig-
nificantly increased risk of 30-day readmission either
due to any cause or specifically due to pneumonia
(Table 6).
Discussion
This study has shown that in adults admitted to hospital
with a diagnosis of CAP, the in-hospital mortality was
higher in those who had received antibiotic treatment
immediately prior to admission. This finding remained
even when controlling for variables that have tradition-
ally been shown to be of prognostic value in CAP, such
as co-morbidity, age, and the CURB-65 score. The
clinical relevance of this lies in the fact that currently,
national guidance for the management of CAP does not
recommend a change in management strategy when
clinicians in the emergency department encounter a
patient with pneumonia “pre-treated” with antibiotics in
the community. The evidence associating the outcome
from CAP specifically with antibiotic pre-treatment has
been conflicting to date [7–14]. A single-centre study of
2179 subjects hospitalized with CAP reported that 17%
had been treated with antibiotics prior to admission, a
proportion similar to the current study’s findings, yet no
significant differences were noted in 30-day mortality,
length of stay, or incidence of intensive care unit (ICU)
admission, although the frequency of bacteremia was
less in the “pre-treatment” group [7]. However, in con-
trast to the current study, the “prior antibiotic” group
had less in terms of co-morbidity in the form of diabetes
and cardiac disease as well as a significantly lower pro-
portion of “severe” pneumonia according to CURB-65
criteria, which may explain the authors’ findings. In
contrast to the current study’s cohort, this group had less
severe pneumonia as evidenced by lower CURB65 scores.
Table 2 Comparison of subjects who died in-hospital against those surviving to discharge
Discharged from hospital Died in-hospital
n = 5432 n = 916
Charlson Co-morbidity Index 4 (1–14) 14 (4–23) P < 0.001
Gender
Female 2761 (50.8%) 440 (48%) P = 0.12
Male 2671 (49.2%) 476 (52%)
Age (mean/SD years) 71 (16) 80 (11) P < 0.001
History of MI n (%) 499 (9.2%) 137 (15.0%) P < 0.001
History of CVA n (%) 248 (4.6%) 81 (8.8%) P < 0.001
History of Congestive Cardiac Failure n (%) 733 (13.5%) 290 (31.7%) P < 0.001
History of Dementia n (%) 581 (10.7%) 178 (19.4%) P = < 0.001
History of Diabetes n(%) 1004 (18.5%) 161 (17.6%) P = 0.51
History of Liver Disease n (%) 45 (0.8%) 9 (1.0%) P = 0.64
History of Pulmonary Disease n (%) 2564 (47.2%) 405 (44.2%) P = 0.09
History of Cancer n (%) 642 (11.8%) 166 (18.1%) P < 0.001
History of Diabetes Mellitus with complications n (%) 58 (1.1%) 8 (0.9%) P = 0.59
History of Paraplegia n (%) 95 (1.7%) 27 (2.9%) P = 0.02
History of Renal Disease n (%) 740 (13.6%) 219 (23.1%) P < 0.001
History of Metastatic Cancer n (%) 208 (3.8%) 75 (8.2%) P < 0.001
History of Severe Liver Disease n (%) 18 (0.3%) 6 (0.7%) P = 0.14
Admission CURB 65 score (n = 3993; 2355 cases not documented) CURB 0: 538 (15.3%) CURB 0: 9 (1.9%) P < 0.001
CURB 1: 863 (24.6%) CURB 1: 43 (8.9%)
CURB 2: 1127 (32.1%) CURB 2: 142 (29.4%)
CURB 3: 799 (22.8%) CURB 3: 193 (40%)
CURB 4: 163 (4.6%) CURB 4: 81 (16.8%)
CURB 5: 20 (0.6%) CURB 5: 15 (3.1%)
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Their patients also had less diabetic and cardiovascular
comorbidity. The issue of prior outpatient therapy was
addressed by Van de Garde who reported that of 1096
subjects hospitalized for CAP over a 5 year period in the
Netherlands, 27% had been “pre-treated” with antibiotics
with no significant difference reported in mortality [8].
However, the diagnosis of CAP was based on ICD coding
which has been shown to carry limitations in diagnostic
accuracy [9]. In contrast, the current study’s AQ cohort
had a more stringent process to ensure an accurate diag-
nosis of CAP; i.e. confirmed radiological diagnosis of CAP
verified by an independent reviewer at the time of data
Table 3 Comparison of subjects “pre-treated” with antibiotics prior to admission against those not “pre-treated”
Not pre-treated with antibiotics
pre-admission (n = 4973)
Pre-treated with antibiotics
pre-admission (n = 1059)
P value
Age 72.41 (16.71) 72.13 (15.88) 0.61
Gender
Female 2484 (49.9%) 564 (53.3%) 0.051
Male 2498 (50.1%) 495 (46.7%)
In-hospital Mortality 658 (13) 197 (19) < 0.001
Length Of Stay (LOS) 5 (2–11) 5 (3–11) 0.15
Admission CURB-65 score (n = 3993; 2355 cases not documented) CURB 0:463 (14%) CURB 0: 84 (14%) 0.72
CURB 1: 780 (23%) CURB 1: 126 (21%)
CURB 2: 1073(32%) CURB 2: 196 (32%)
CURB 3: 830 (25%) CURB 3: 162 (27%)
CURB 4: 211(6%) CURB 4: 33 (5%)
CURB 5: 29 (1%) CURB 5: 6 (1%)
Charlson Co-morbidity Index 4 (3–16) 7 (3–17) 0.001
History of MI 489 (9.8) 109 (10.3) 0.65
History of CVA 248 (5) 63 (5.9) 0.20
History of CCF 792 (15.1) 197 (18.6) 0.005
History of Pulmonary Disease 2314 (46.5) 498 (47) 0.78
History of Renal Disease 709 (14.3) 190 (17.9) 0.002
History of Diabetes Mellitus 922 (18.5) 183 (17.3) 0.34
History of Diabetes Mellitus with complications 54 (1.1) 11 (1) 0.89
History of Dementia 578 (11.6) 144 (13.6) 0.07
History of Paraplegia 93 (1.9) 25 (2.4) 0.30
History of Liver Disease 49 (1) 4 (0.4) 0.054
History of Severe Liver Disease 20 (0.4) 3 (0.3) 0.57
History of Cancer 633 (12.7) 133 (12.6) 0.88
History of Metastatic Cancer 224 (4.5) 48 (4.5) 0.97
Table 4 Multivariate analysis of variables associated with in-hospital mortality
Variable Adjusted odds ratio 95% confidence interval Significance
Age 1.04 (1.03, 1.04) P < 0.001
Male Gender 1.17 (1.01, 1.37) P = 0.04
Pre-treatment with antibiotics 1.43 (1.19, 1.71) P = 0.001
History of Cerebrovascular Accident (CVA) 1.55 (1.17, 2.05) P = 0.002
History of Congestive Cardiac Failure (CCF) 2.28 (1.91, 2.71) P < 0.001
History of Dementia 1.42 (1.15, 1.74) P = 0.001
History of Renal Disease 1.27 (1.06, 1.54) P = 0.01
History of Cancer 1.73 (1.41–1.72) P < 0.001
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entry, coupled with the requirement that a documented
diagnosis of CAP had to have been made by a senior phys-
ician within the first 24 h following admission to hospital.
Similarly, a smaller retrospective North American study of
733 subjects admitted with CAP to 2 centres did not re-
port a significant difference in mortality in the 17% of sub-
jects who had received antibiotics prior to admission [13].
However, the definition of “prior antibiotic therapy” in this
study included subjects who had received antibiotics
within 30 days of the admission, as opposed to the current
study where only those who were being treated with anti-
biotics within 24 h of admission were captured. Further-
more, the North American study excluded those who
were nursing home residents and 32% of the pre-treated
cohort was administered fluoroquinolones prior to admis-
sion, which would not be normal practice in the UK where
the prescription of antibiotics in the primary care setting
is more tightly regulated. A prospective single-centre
study of 3364 subjects reported that similar to the findings
of this study, 18% of subjects had been administered anti-
biotics in the 24 h prior to admission [10]. In contrast to
the data from the current study, the authors reported im-
proved outcomes in the “pre-treated” cohort, namely a re-
duced need for mechanical ventilation and a decrease in
the incidence of septic shock, but no difference in overall
mortality. However, such a difference may be explained
due to this cohort having a higher incidence of “low sever-
ity” pneumonia (defined as a CURB score of 0–1) standing
at 50% and 56% in the non-pretreated and pretreated
groups, respectively, in comparison to 14% observed in
both groups of the current cohort. Furthermore, as with
earlier studies, the range of antibiotics administered in
primary care settings was more diverse when compared to
the UK (including cefotaxime and quinolones) and in
addition, this study specifically excluded nursing home
residents. Similarly, in the earlier described study of 733
pneumonia cases admitted to 2 US hospitals, the 30-day
mortality in the entire cohort was reported to be 8.1% and
55% of the study population had pneumonia classified as
“low risk”, which suggests there may be differences in the
study population from that represented in the current
study’s cohort [13]. Another retrospective study of more
than 18,000 patients aged over 65 years hospitalized with
pneumonia reported that 24.4% had received pre-hospital
antibiotic therapy [14]. This study reported that pre-
hospital antibiotics were likely to have been administered
if subjects were female gender and from a “skilled nursing
facility” and were more likely to have had decreased pneu-
monia severity when compared with those not receiving
antibiotics pre-hospital, whilst the current study reported
a non-significant trend to female gender and pre-hospital
antibiotic therapy but not with pneumonia severity when
using CURB-65 as opposed to the pneumonia severity
index (PSI). Unsurprisingly, the authors reported that the
subjects administered pre-hospital antibiotics were less
likely to be admitted to intensive care although this may
be explained by this group presenting with less severe
CAP according to PSI score. Interestingly, the “pre-
treated” group had higher 30-day mortality if antibiotics
were administered within 8 h of hospital admission
compared to administration beyond 8 h from admission.
Table 5 Analysis of subjects with a documented CURB-65 score
Variable Regression coefficient Adjusted odds ratio 95% confidence interval Significance
Age 0.03 1.03 (1.02, 1.04) P < 0.001
CCI 0.02 1.02 (1.00, 1.03) P = 0.008
Pre-treatment with antibiotics 0.43 1.54 (1.20, 1.99) P = 0.001
History of CCF 0.49 1.62 (1.22, 2.17) P = 0.001
History of Cancer 0.34 1.40 (1.01, 1.95) P = 0.046
History of metastatic cancer 0.64 1.88 (1.03, 3.47) P = 0.04
CURB65 0 Reference
CURB65 1 0.42 1.53 (0.72, 3.26) P = 0.27
CURB65 2 1.05 2.85 (1.37, 5.92) P = 0.005
CURB65 3 1.56 4.77 (2.38, 9.97) P < 0.001
CURB65 4 2.25 9.48 (4.37, 20.56) P < 0.001
CURB65 5 2.83 16.88 (6.22, 45.77) P < 0.001
Table 6 The relationship between 30-day readmission and
“pre-treatment” with antibiotics
Readmission due to any cause
No Yes
Not “pre-treated” 4118 (82.4%) 878 (82.5%) P = 0.94
“Pre-treated” 855 (17.6%) 181 (17.5%)
Readmission with Pneumonia
No Yes
Not “pre-treated” 3877 (83.4%) 438 (83.1%) P = 0.88
“Pre-treated” 273 (16.6%) 89 (16.9%)
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As in previous studies, the in-hospital mortality was con-
siderably lower than reported in the current study’s
cohort, standing at 7%, which again suggests that the
study population may have been less “sick” at presentation
than the cohort from this current study.
There are a number of potential mechanisms to ex-
plain these observations and whether these differences
in observed outcome can be explained solely by treat-
ment failure at a microbiological level or reflect a com-
plex interplay between co-morbidities and the host
microbiome require further study. The subjects admitted
following antibiotic treatment in primary care could
have represented a “sicker” cohort with a greater burden
of co-morbidity, as evidenced by the fact that there was
a higher incidence of cardiac failure and renal disease in
this group. However, interestingly, the CURB-65 score, a
widely used measure to risk stratify CAP at admission in
UK hospitals, was not found to differ significantly be-
tween the 2 groups nor did age itself when taken separ-
ately. Despite there being no observed difference in CAP
severity, as measured by CURB65 score, between the
pre-treated and non-pre-treated groups it is possible
there are unmeasured markers of severity. The study ob-
served a statistically significant increase in the frequency
of renal and cardiac disease in pre-treated patients.
These conditions cause fluid overload with associated
changes in antibiotic absorption via the gut and across
“wet” lungs. These conditions cause increased suscepti-
bility to CAP and possible reduced efficacy of therapy
and as a consequence primary care physicians are more
likely to prescribe prompt antibiotics. Whilst the UK has
a low level of pneumococcal resistance to beta-lactam
antibiotics, a proportion of this cohort were also diag-
nosed with underlying chronic lung disease which may
suggest the presence of an expanded range of pathogens
causing CAP such as Haemophilus influenzae, and
Pseudomonas aeruginosa [15]. An intriguing mechanism
to explain these findings may lie in the fact that the trad-
itional concept of a “sterile” lung has been challenged of
late, and the pathogenesis of pneumonia in an individual
has been linked to alterations in the lung microbiome
[16]. Further studies are required to better understand
the effect prior antibiotic therapy has in terms of causing
imbalances in the lung biome in the specific setting of
inpatients hospitalized with CAP. Irrespective of any po-
tential mechanism, the authors propose that clinicians
adopt a degree of vigilance when managing this cohort of
patients following hospital admission and that such pa-
tients warrant close monitoring with early input from se-
nior physicians and clinical microbiology. However,
whether antibiotic prescribing should differ from estab-
lished guidance when managing such a cohort of CAP pa-
tients from those who have not received antibiotics prior
to admission requires more detailed prospective study [17].
A particular strength of this study is that the Advan-
cing Quality database is a nationally recognized initiative
adopted by multiple NHS hospitals in the northwest of
England and data quality is subject to strict audit and
regulation. The diagnosis of CAP was more robust in
the study as it was not based solely on ICD coding as in
previous studies, but from analysis of medical records
documenting a diagnosis of CAP made by a consultant
physician, exclusion of those with a normal chest radio-
graph from the AQ database, and an independent review
at the time of data entry ensuring the official chest X-ray
report was compatible with a diagnosis of CAP. Further-
more, subjects with a “Palliative” code were also
excluded from the AQ analysis, as were cases of HAP
and “Aspiration” pneumonia; hence, for the cases en-
tered, CAP was more likely to play a more significant
role in terms of contributing to in-hospital mortality.
The fact that this multi-centre study involved 9 hospitals
and more than 6000 subjects adds to the strength of this
data. Furthermore, all the 9 hospitals studied were re-
quired to submit all cases of CAP to the AQ program
during the study period, thus reducing the possibility of
selection bias. The age, pattern of comorbidities and in-
patient mortality was similar to that reported in the BTS
audit cohort although lung disease was more frequent in
this current group [1].
Limitations to this study include that antibiotic pre-
treatment was ascertained by inspection of medical and
hospital pharmacy records, which may have missed cer-
tain cases where documentation did not take place. The
analysis did not take into account differences in duration
of antibiotic pre-treatment as a predictor of outcome; i.e.
the study did not distinguish between the scenario of a pa-
tient admitted with CAP having been administered simply
one dose of antibiotic prior to admission (therefore not
necessarily deemed to have “failed” an antibiotic course in
the community), compared to a different situation where
a patient receives several courses of antibiotics in the
weeks prior to admission yet still requires admission due
to inadequate resolution of symptoms. Furthermore, the
dose and type of antibiotic prescribed in primary care was
not studied and this could have influenced outcome.
However, in the UK, prescribing options in primary care
are highly regulated according to national guidelines as
opposed to “physician discretion” where the vast majority
of patients will have received amoxicillin either as mono-
therapy or with clarithromycin or monotherapy with
doxycycline or clarithromycin [18]. This study’s dataset
did not contain any specific information regarding micro-
biology testing from the cohort during the hospital admis-
sion, hence specific associations between microbiology
results and the impact of antibiotic pre-treatment on out-
comes were not examined. This requires detailed pro-
spective study. A further limitation is that in this study’s
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cohort, the “CURB-65 score” was not documented in 37%
of cases. However, when taking only those cases where the
“CURB-65” score had been documented, antibiotic pre-
treatment still emerged as significant following multivari-
ate analysis. This limitation should also be balanced with
the large sample size of the study population coupled with
the fact that the statistical analysis controlled for
comorbidity.
Furthermore, whilst, the CURB-65 score itself represents
a standard of care in terms of CAP severity assessment, the
relationship between antibiotic pre-treatment and other
markers of adverse outcome (such as ICU admission, inci-
dence of multi-organ failure and oxygenation) was not ex-
amined. In addition, whilst this study did control for key
conditions known to result in immunosuppression, such as
hematological malignancy, it did not directly study the ef-
fect of immunosuppressive and other medications associ-
ated with an increased incidence CAP [19, 20]. Another
limitation is that this dataset did not record detailed surro-
gate markers reflecting the severity of co-morbidity which
may have influenced outcome, such as nursing home resi-
dence, frequency of hospital admissions in the preceding
12 months, or number of outpatient attendances; e.g. for
dialysis. However, the 30-day readmission rate due to any
cause was not found to differ between the antibiotic pre-
treatment group and those subjects not pre-treated with
antibiotics prior to admission.
Conclusion
In summary, this study reports a higher mortality for
subjects hospitalized with CAP who had received anti-
biotic therapy in the community immediately prior to
hospital admission, a relationship maintained independ-
ent of comorbidity and disease severity. Such patients
require close clinical monitoring in hospital with early
specialist input. Future prospective studies should en-
deavor to determine the underlying mechanisms respon-
sible for this observation focusing on factors such as
disease etiology, microbiological variables, alterations to
the lung microbiome, and adherence to therapy.
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